Volume 33, Issue 2 (6-2024)
JGUMS 2024, 33(2): 202-215 |
Back to browse issues page
Research code: 2079
Ethics code: IR.GUMS>REC.1397.092
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Pourkazem S, Sharifi Rad M, Baghersalimi A, Salehi S, Enshaei M, Aminzadeh V, et al . Investigating the Effect of Iron Chelation Therapy With Deferasirox on Liver Aminotransferases Levels in Transfusion-dependent β-thalassemia Patients. JGUMS 2024; 33 (2) :202-215
URL: http://journal.gums.ac.ir/article-1-2621-en.html
URL: http://journal.gums.ac.ir/article-1-2621-en.html
Shayan Pourkazem1 
, Mohammadreza Sharifi Rad1 , Adel Baghersalimi1 , Soodeh Salehi1 , Mercedeh Enshaei1 , Vahid Aminzadeh1 , Behrang Motamed2 , Bahram Darbandi *1
, Mohammadreza Sharifi Rad1 , Adel Baghersalimi1 , Soodeh Salehi1 , Mercedeh Enshaei1 , Vahid Aminzadeh1 , Behrang Motamed2 , Bahram Darbandi *1
1- Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
2- Department of Internal Medicine, Razi Hospital, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
2- Department of Internal Medicine, Razi Hospital, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Abstract: (1706 Views)
Background Various body tissues of β-thalassemia patients are exposed to the destructive effects of iron overload due to chronic blood transfusions. Therefore, the decision to start regular blood transfusion therapy for these patients often leads to the administration of iron chelators. Deferasirox as an orally effective iron-chelating drug could cause some therapy-related adverse events, such as increased liver enzymes, serum creatinine, and gastrointestinal bleeding.
Objective This study evaluates the effect of deferasirox on serum levels of ferritin and liver aminotransferases in transfusion-dependent β-thalassemia patients.
Methods In this study, changes in the serum levels of ferritin and liver aminotransferases in β-thalassemia patients receiving deferasirox, who were referred to the thalassemia department of the 17 Shahrivar Hospital and Beesat Clinic in Rasht City, Iran, have been evaluated, retrospectively. In this regard, 104 β-thalassemia major patients over two years of age receiving regular blood transfusions and deferasirox for at least two consecutive years were enrolled. Information of patients, including age, sex, blood transfusion frequency, deferasirox administration duration and dosage, and serum levels of ferritin and liver enzymes between baseline and at least two years after iron chelation therapy with deferasirox was recorded.
Results The decreased serum levels of ferritin (P=0.017), aspartate aminotransferase (P=0.0001), and alanine aminotransferase (P=0.015) in the last blood testing after deferasirox therapy were statistically significant. However, there was no statistical significance between the decreased serum levels of liver aminotransferases and factors, including age, sex, blood transfusion frequency, duration, and dosage of deferasirox administration.
Conclusion After a few months of taking defrazirox, rather than causing mild and rare liver complications, it can have a protective role for the liver against iron overload in the body and significantly reduce liver aminotransferase.
Objective This study evaluates the effect of deferasirox on serum levels of ferritin and liver aminotransferases in transfusion-dependent β-thalassemia patients.
Methods In this study, changes in the serum levels of ferritin and liver aminotransferases in β-thalassemia patients receiving deferasirox, who were referred to the thalassemia department of the 17 Shahrivar Hospital and Beesat Clinic in Rasht City, Iran, have been evaluated, retrospectively. In this regard, 104 β-thalassemia major patients over two years of age receiving regular blood transfusions and deferasirox for at least two consecutive years were enrolled. Information of patients, including age, sex, blood transfusion frequency, deferasirox administration duration and dosage, and serum levels of ferritin and liver enzymes between baseline and at least two years after iron chelation therapy with deferasirox was recorded.
Results The decreased serum levels of ferritin (P=0.017), aspartate aminotransferase (P=0.0001), and alanine aminotransferase (P=0.015) in the last blood testing after deferasirox therapy were statistically significant. However, there was no statistical significance between the decreased serum levels of liver aminotransferases and factors, including age, sex, blood transfusion frequency, duration, and dosage of deferasirox administration.
Conclusion After a few months of taking defrazirox, rather than causing mild and rare liver complications, it can have a protective role for the liver against iron overload in the body and significantly reduce liver aminotransferase.
Review Paper: Research |
Subject:
Special
Received: 2023/10/1 | Accepted: 2023/12/23 | Published: 2024/07/1
Received: 2023/10/1 | Accepted: 2023/12/23 | Published: 2024/07/1
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the
Creative Commons Attribution License (CC-By-NC),which permits use, distribution, and reproduction in any medium,
provided the original work is properly cited and is not used forcommercial purposes.
Contact Information
